Rentschler Biopharma extends its cell line development solutions for difficult-to-express proteins

Rentschler announces the signing of a commercial license agreement for the production of highly complex proteins.


Rentschler Biopharma, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Horizon Discovery, a global leader in the application of gene editing and gene modulation for cell line engineering, announced the signing of a commercial license agreement.


Under the terms of the agreement, Horizon's CHOSOURCE™ platform will be used in combination with Rentschler Biopharma's novel in-house process for cell line development for difficult-to-express proteins. Horizon's gene-edited Glutamine Synthetase ("GS") knockout Chinese Hamster Ovary (CHO) K1 cGMP-compliant cell line will complement Rentschler Biopharma's existing service offering, providing a royalty-free, state-of-the-art alternative for the production of highly complex proteins. This will support researchers from early drug development through commercial manufacturing.


By entering into the agreement, Horizon and Rentschler Biopharma aim to empower organizations of all sizes, from large pharmaceutical companies to clinical stage biotechs and early stage startups, to drive efficiencies in biotherapeutic manufacturing.


Rentschler Biopharma's integrated platform process, together with Horizon's cell line, will provide innovative and tailored solutions to translate complex medical research into outstanding biopharmaceuticals. This will elevate the standard of protein expression and allow clients to access a robust and flexible approach for designer protein therapeutics, from concept to market.



(Pressrelease Rentschler Biopharma/Horizon Discovery Group, 18.05.2020)